CD33 and cancer: CD3/CD33 BsAb, in which one arm targets the CD3 molecule on the surface of T cells and the other arm targets the CD33 antigen on the surface of cancer cells, in this way, the BsAb close the distance between T cells and cancer cells, directing T cells to kill cancer cells directly [141].